NervGen Pharma (NASDAQ:NGEN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of NervGen Pharma (NASDAQ:NGEN) from a sell rating to a hold rating in a research note released on Monday morning.

Several other analysts have also recently weighed in on the company. Zacks Research upgraded NervGen Pharma to a “hold” rating in a report on Wednesday, April 29th. HC Wainwright raised NervGen Pharma to a “strong-buy” rating in a research note on Tuesday, April 28th. Stifel Nicolaus upgraded shares of NervGen Pharma to a “strong-buy” rating in a report on Thursday, April 23rd. Weiss Ratings started coverage on shares of NervGen Pharma in a research report on Friday, April 24th. They set a “sell (d-)” rating on the stock. Finally, Leerink Partners assumed coverage on shares of NervGen Pharma in a report on Monday, July 13th. They set an “outperform” rating and a $10.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, NervGen Pharma has a consensus rating of “Moderate Buy” and an average price target of $14.00.

NervGen Pharma Stock Performance

NASDAQ NGEN opened at $1.72 on Monday. The firm has a market cap of $138.69 million and a P/E ratio of -19.11. NervGen Pharma has a twelve month low of $1.59 and a twelve month high of $6.30. The firm’s fifty day moving average price is $2.15.

NervGen Pharma (NASDAQ:NGEN) last issued its earnings results on Friday, May 15th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02).

About NervGen Pharma

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.